According to DPI developer Iconovo, the company has received a grant worth SEK 670,000 from the EU’s Innowwide initiative, which encourages small and medium-sized EU companies to enter international markets. The grant will fund a market study this year that will evaluate opportunities for Iconovo to partner with Japanese companies to sell its products and services in Japan. In 2024, Iconovo received a similar Innowwide grant to explore the South Korean market.
Iconovo develops dry powder inhalation devices including the ICOpre, ICOone, ICOres, and ICOone Nasal, as well as DPI formulations. In May 2024, the company announced that it would develop dry powder GLP-1 inhalation products for the treatment of obesity. Recently, Iconovo and Lonza announced a partnership on development of a dry powder biologic for delivery by the ICOone device.
Iconovo CEO Johan Wäborg commented, “Last year, we carried out a similar project in South Korea with great success and now we are moving forward with Japan to further increase our presence in the important Asian markets. Our interactions with Japanese companies have generated great interest and significant potential for the development of inhaled drugs, and the grant from Innowwide gives us the opportunity to, in a structured way, establish ourselves in one of the world’s largest pharmaceutical markets.”
Read the Iconovo press release
